Home | About us | Editorial board | Search | Ahead of print | Current issue | Archives | Submit article | Instructions | Subscribe | Advertise | Contacts | Login 
  Users Online: 2077 Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  

    Article Cited by others


Metastatic breast cancer: Endocrine therapy landscape reshaped

Salkeni Mohamad Adham, Hall Samantha June

Year : 2017| Volume: 7| Issue : 4 | Page no: 144-152

   This article has been cited by
1 Prediction of fulvestrant efficacy in patients with advanced breast cancer: retrospective-prospective evaluation of the predictive potential of a multigene expression assay
Troels Dreier Christensen,Anna Sofie Kappel Buhl,Ib Jarle Christensen,Ida Kappel Buhl,Eva Balslev,Ann S. Knoop,Hella Danø,Vesna Glavicic,Adam Luczak,Sven Tyge Langkjer,Søren Linnet,Erik Hugger Jakobsen,Jurij Bogovic,Bent Ejlertsen,Annie Rasmussen,Anker Hansen,Steen Knudsen,Peter Buhl Jensen,Dorte Nielsen
Breast Cancer. 2019;
[Pubmed]  [Google Scholar] [DOI]
2 Real-world effectiveness of fulvestrant monotherapy as first endocrine treatment in patients with metastatic breast cancer
Karen E. Skinner,Temitope Olufade,Mark S. Walker,Lee S. Schwartzberg
The Breast Journal. 2019;
[Pubmed]  [Google Scholar] [DOI]
3 Novel Agents for the Management of Endocrine Resistant Breast Cancer
Sonya Reid-Lawrence,Ingrid A. Mayer
Current Breast Cancer Reports. 2018; 10(4): 274
[Pubmed]  [Google Scholar] [DOI]


Read this article